BioCentury
ARTICLE | Company News

Eli Lilly, Denovo Biopharma deal

November 10, 2014 8:00 AM UTC

Denovo acquired enzastaurin ( DB102) from Eli Lilly. In 2013, Lilly discontinued development of enzastaurin (formerly LY317615) after the compound missed the primary endpoint in the Phase III PRELUDE...